06 Validation of risk prediction model
|
|
- Horatio Woods
- 8 years ago
- Views:
Transcription
1 HA Territory-wide PCI Audit Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007
2 Background Participants: All HA hospitals via CCLs Mechanism: Prospective Comparative Audit Audit Period: 1 Jan Dec 2006 Audit Tools: PHCA s audit form Supplemented by Discharge summary epr consultation note Laboratory results (LIS) Death Registry On-site random record check
3 Objectives Compare baseline characteristics Compare standardized mortality and complication ratios among 10 CCLs Identify risk factors related to post-operation operation mortality and complication within 72 hours Validate the risk prediction model for post-pci mortality/complications
4 Baseline Characteristics N= 3,904 N= 4,894 N= 4,784 N= 5,036 Male Sex 2,870 (74%) 3,639 (74%) 3,539 (74%) 3,709 (74%) Hypercholesterolemia 2,815 (72%) 3,726 (76%) 3,016 (63%) 3,354 (67%) Hypertension 2,573 (66%) 3,211 (66%) 3,039 (64%) 3,184 (63%) Smoking History 2,191 (56%) 2,567 (53%) 2,260 (47%) 2,315 (46%) Age 1,442 (37%) 1,882 (39%) 2,069 (43%) 2,197 (44%) Diabetes Mellitus 1,553 (40%) 1,903 (39%) 1,829 (38%) 1,954 (39%) Previous PCI 1,252 (32%) 1,604 (33%) 1,525 (32%) 1,599 (32%) CVA 297 (8%) 412 (8%) 284 (6%) 314 (6%) Renal Failure 180 (5%) 252 (5%) 236 (5%) 241 (5%)
5 ACS other than AMI, 678, 17.4% Primary (for AMI), 152, 3.9% Rescue (for AMI), 92, 2.4% Unplanned redo PCI, 7, 0.2% Case mix ACS other than AMI, 864, 17.7% Primary (for AMI), 145, 3.0% Rescue (for AMI), 44, 0.9% Unplanned redo PCI, 6, 0.1% Elective, 3835, 78.4% (3904 cases) ACS other than AMI, 627, 13.1% Primary (for AMI), 166, 3.5% Elective, 2975, 76.2% Rescue (for AMI), 71, 1.5% (4894 cases) ACS other than AMI, 698, 13.9% Primary (for AMI), 159, 3.2% Rescue (for AMI), 79, 1.6% 2005* (4784 cases) Elective, 3920, 81.9% 2006* (5036 cases) Elective, 4100, 81.4% * Unplanned redo PCI are not categorized in 2005 and 2006 data
6 Severity of disease >2 vessels attempted, 226, 5.8% >2 vessels attempted, 377, 7.7% 2 vessels attempted, 1014, 26.0% 2 vessels attempted, 1349, 27.6% 2003 (3904 cases) 1 vessel attempted, 2664, 68.2% 2004 (4894 cases) 1 vessel attempted, 3168, 64.7% >2 vessels attempted, 294, 6.2% >2 vessels attempted, 413, 8.2% 2 vessels attempted, 1333, 27.9% 2 vessels attempted, 1387, 27.5% 2005 (4772 cases) (12 cases are excluded due to missing and invalid value) 1 vessel attempted, 3145, 65.9% 2006 (5036 cases) 1 vessel attempted, 3236, 64.3%
7 Characteristics of the worst lesion Type A, 481, 12.3% Type A, 440, 9.0% Type C, 1313, 33.6% Type C, 1672, 34.2% Type B1, 806, 20.6% Type B1, 1155, 23. 6% 2003 (3904 cases) Type B2, 1304, 33.4% 2004 (4894 cases) Type B2, 1627, 33.2% Type C, 1467, 30.7% Type A, 239, 5.0% Type B1, 1150, 24.0% Type C, 1804, 35.8% Type A, 336, 6.7% Type B1, 966, 19.2% 2005 (4784 cases) Type B2, 1928, 40.3% 2006 (5036 cases) Type B2, 1930, 38.3%
8 Angiographic result Angiographic Result Successful 3,651 (94%) 4,568 (93%) 4,578 (96%) 4,803 (95%) Partially Successful 115 (3%) 182 (4%) 78 (2%) 100 (2%) Unsuccessful 138 (4%) 144 (3%) 128 (3%) 133 (3%) Total 3,904 (100%) 4,894 (100%) 4,784 (100%) 5,036 (100%)
9 Use of PCI devices/drugs Balloon Stent Rotablator DCA Distal Protection Device Thrombectomy Device IABP/CPS Gp 2b3a Inhibitor Closure Devices (N=3,904) (N=4,894) (N=4,784) (N=5,036) 3,468 (89%) 4,458 (91%) 4,295 (90%) 4,622 (92%) 3,194 (82%) 4,472 (91%) 4,491 (94%) 4,756 (94%) 59 (2%) 55 (1%) 34 (1%) 45 (1%) 6 (0.2%) 143 (3%) 7 (0.2%) 1 (0.02%) 123 (3%) 111 (2%) 83 (2%) 71 (1%) 59 (2%) 64 (1%) 47 (1%) 90 (2%) 65 (2%) 105 (2%) 83 (2%) 89 (2%) 154 (4%) 116 (2%) 162 (3%) 164 (3%) 379 (10%) 478 (10%) 977 (20%) 1,204 (24%)
10 Major Complications within 72 hours on event basis (direct and indirect procedure causes included) No. of cases Death 3, (0.6%) 4, (0.61%) 4, (0.7%) 5, (0.5%) Other major complications 45(1.2%) 89 (1.8%) 76 (1.6%) 82 (1.6%) MI-Non Q 21 (0.5%) 50 (1.0%) 31 (0.7%) 52 (1.0%) MI-Q wave 7 (0.2%) 5 (0.1%) 10 (0.2%) 8 (0.2%) Unplanned CABG 1 (0.03%) 6 (0.1%) 4 (0.1%) 3 (0.1%) Unplanned Re-PCI 10 (0.3%) 6 (0.1%) 8 (0.2%) 8 (0.2%) Stroke 0 (0%) 2 (0.04%) 4 (0.1%) 1 (0.02%) Bleeding with Hb Drop of >=3g/dl 6 (0.2%) 10 (0.2%) 12 (0.3%) 7 (0.1%) Cardiac Tamponade 5 (0.1%) 14 (0.3%) 11 (0.2%) 12 (0.2%) Vascular surgery or repair 2 (0.1%) 2 (0.04%) 1 (0.02%) 2 (0.04%)
11 Complications All Patients,2003~06 Indications Elective ACS other than AMI Primary (for AMI) Rescue (for AMI) Unplanned redo PCI* No. of cases Death 13 (0.1%) 41 (1.4%) 39 (6.3%) 17 (5.9%) 1 (7.7%) Other major complications 202 (1.4%) 60 (2.1%) 21 (3.4%) 9 (3.1%) 0 (0%) MI-Non Q 121 (0.8%) 31 (1.1%) 2 (0.3%) MI-Q wave 21 (0.1%) 4 (0.1%) 4 (0.6%) 1 (0.4%) Unplanned CABG 6 (0.04%) 7 (0.2%) 1 (0.4%) Unplanned Re-PCI 16 (0.1%) 7 (0.2%) 8 (1.3%) 1 (0.4%) Stroke 3 (0.02%) 2 (0.1%) 2 (0.3%) Bleeding with Hb Drop of >=3g/dl 22 (0.2%) 8 (0.3%) 3 (0.5%) 2 (0.7%) Cardiac Tamponade 27 (0.2%) 8 (0.3%) 2 (0.3%) 5 (1.8%) Vascular surgery or repair 5 (0.03%) 2 (0.1%) * "Unplanned redo PCI" is not categorized in 2005 and 2006 data.
12 Mortality & Other major complications Primary PCI (for AMI) done Overall No. of cases Death 8 (5.3%) 11 (7.6%) 12 (7.2%) 8 (5%) 39 (6.3%) Other major complications 2 (1.3%) 6 (4.1%) 6 (3.6%) 7 (4.4%) 21 (3.4%) MI-Non Q 1 (0.7%) 1 (0.6%) 2 (0.3%) MI-Q wave 1 (0.7%) 1 (0.6%) 2 (1.3%) 4 (0.6%) Unplanned CABG 0 (0%) Unplanned Re-PCI 2 (1.3%) 2 (1.4%) 1 (0.6%) 3 (1.9%) 8 (1.3%) Stroke 2 (1.2%) 2 (0.3%) Bleeding with Hb Drop of >=3g/dl 1 (0.7%) 1 (0.6%) 1 (0.6%) 3 (0.5%) Cardiac Tamponade 1 (0.7%) 1 (0.6%) 2 (0.3%) Vascular surgery or repair 0 (0%) Among 622 cases with Primary PCI (for AMI) done, 3 cases have missing information on other major complications, and 2 of the aforesaid cases also have missing information on death.
13 Mortality & Other major complications Intercurrent Cardiogenic Shock No. of cases Overall Death 10 (17.5%) 14 (21.9%) 19 (27.1%) 11 (18%) 54 (21.3%) Other major complications 2 (3.5%) 6 (9.4%) 5 (7.1%) 0 (0.0%) 13 (5.1%) MI-Non Q 1 (1.6%) 1 (1.4%) 2 (0.8%) MI-Q-wave 1 (1.8%) 1 (0.4%) Unplanned CABG 0 (0%) Unplanned Re-PCI 2 (2.9%) 2 (0.8%) Stroke 2 (2.9%) 2 (0.8%) Bleeding with Hb Drop of >=3g/dl 2 (3.1%) 1 (1.4%) 3 (1.2%) Cardiac Tamponade 1 (1.8%) 3 (4.7%) 4 (1.6%) Vascular surgery or repair 0 (0%) Among 253 cases with Intercurrent cardiogenic shock, 3 cases have missing information on death and other major complications.
14 Post-PCI PCI Mortality, 2003~ Overall No. of cases 3,904 4,894 4,784 5,036 18,618 Deaths within 72 hours 23 (0.6%) 30 (0.6%) 33 (0.7%) 25 (0.5%) 111(0.6%) Deaths within 30 days * 50 (1.3%) 66 (1.3%) 79 (1.7%) 69 (1.4%) 264(1.4%) * In cases with incomplete death date, impute month end when death day is missing and impute year end when death month is missing.
15 Univariate & Multivariate Analyses (2003 ~ 2006)
16 Mortality within 72 hours
17 Mortality Univariate analysis (2003 ~ 06) No. of cases = 18,553 Deaths: N=111 (0.6%) A. Pre-Intervention Status Heart Failure Sustained Ventricular Tachycardia or Ventr icular Fibr illation N(%) None/Other HF/Past Hx of HF 18, (0.3%) Intercurrent Cardiogenic Shock (21.6%) None 18, (0.4%) Intercurrent VT/VF (within 24hrs) (13.3%) All other VT/VF excluding 1 o VT/VF (1.2%) Angina Type No Angina 1,191 3 (0.3%) <0.01 Major Native Arteries with >=50% lesions No. of cases Death Stable 11,109 9 (0.1%) Unstable 6, (1.6%) no LM involved 17, (0.5%) LM involved (2.7%) p-value <0.01 <0.01 <0.01
18 Mortality Univariate analysis (2003 ~ 06) No. of cases = 18,553 Deaths: N=111 (0.6%) B. Co-morbidity/Risk Factors No. of cases Death N(%) p-value Renal Failure Yes (2.7%) <0.01 No 17, (0.5%) Cerebrovascular Disease Yes 1, (1.7%) <0.01 No 17, (0.5%) Previous Percutaneous Coronary Yes 5, (0.4%) Intervention No 12, (0.7%) Sex Female 4, (0.8%) Male 13, (0.5%) Peripheral Vascular Disease Yes (1.2%) No 17, (0.6%) Hypertension Yes 11, (0.7%) No 6, (0.4%) Age less than 70 10, (0.5%) and over 7, (0.7%) Previous CABG Yes (0.2%) No 18, (0.6%) Smoking History Diabetes Mellitus Family History of premature CAD No 8, (0.6%) Now or Stop<1 Yr 4, (0.7%) Yes but Stop>1 Yr 4, (0.4%) Yes 7, (0.7%) No 11, (0.5%) Yes (0.4%) No 17, (0.6%)
19 Mortality Univariate analysis (2003 ~ 06) No. of cases = 18,553 Deaths: N=111 (0.6%) C. Procedure Summary No. of cases Death N(%) p-value Indications Primary or Rescue AMI/Unplanned redo PCI (6.2%) <0.01 Characteristic of the worst lesion Elective/ACS other than AMI 17, (0.3%) Type A/B1 5, (0.2%) Type B2/C 13, (0.8%) <0.01
20 Mortality Multivariate analysis (2003 ~ 06) No. of PCI cases = 18,393 (Death = 107, 0.58%) OR 95 % C.I. p-value Angina type Unstable Angina no angina or stable angina Vs 6.35 (3.23, 12.47) <.0001 Heart failure Intercurrent Cardiogenic shock None/Other HF/APO/Past Hx of HF Vs (7.03, 20.99) <.0001 Sustained VT/VF Intercurent VT/VF None or other VT/VF Vs 4.28 (2.42, 7.56) <.0001 Major native arteries LM involved No LM involved Vs 2.90 (1.64, 5.13) Cerebrovascular disease Yes No Vs 3.05 (1.78, 5.22) <.0001 Renal failure Yes No Vs 4.15 (2.42, 7.14) <.0001 Indications Goodness-of-fit Primary or Rescue AMI/Unplanned redo PCI Vs Elective/ACS other than AMI 2.76 (1.60, 4.74) p-value of Hosmer & Lemeshow test 0.24 Area under ROC curve 0.90
21 Standardized Mortality Ratio (SMR) (2003~2006) Excluding cases with missing angina type, heart failure, sustained VT/VF, major native arteries, CVA, renal failure or indications No outliers identified Hospital 0.0 A B C D E F G H I J Expected no. of deaths = sum of predicted probability of death from multiple logistic regression model for each hospital
22 Non-death Complication within 72 hours
23 Complication Univariate analysis (2003 ~ 06) No. of cases = 18,448 Complications: N=292 (1.6%) A. Pre-Intervention Status Heart Failure N(%) None/Other HF/Past Hx of HF 18, (1.5%) Intercurrent Cardiogenic Shock (5.2%) Angina Type No Angina 1, (1.6%) <0.05 Major Native Arteries with >=50% lesions Sustained Ventricular Tachycardia or Ventricular Fibrillation No. of cases Complications Unstable 6, (1.9%) Stable 11, (1.4%) no LM involved 17, (1.5%) LM involved (2.5%) None 17, (1.6%) Intercurrent VT/VF (within 24hours) (2.1%) All other VT/VF excluding 1 o VT/VF (1.8%) p-value <0.01 <
24 Complication Univariate analysis (2003 ~ 06) No. of cases = 18,448 Complications: N=292 (1.6%) B. Co-morbidity/Risk Factors Age No. of Complications cases N(%) 70 and over 7, (2.0%) less than 70 10, (1.3%) Yes 1, (2.6%) No 17, (1.5%) p-value <0.01 Cerebrovascular Disease <0.01 Sex Female 4, (2.0%) <0.05 Male 13, (1.5%) Previous CABG Yes (2.7%) <0.05 No 17, (1.5%) Renal Failure Yes (2.3%) No 17, (1.5%) Smoking History No 8, (1.7%) Now or Stop<1 Yr 4, (1.3%) Yes but Stop>1 Yr 4, (1.6%) Hypertension Yes 11, (1.6%) No 6, (1.5%) Peripheral Vascular Disease Yes (1.9%) No 17, (1.6%) Previous Percutaneous Coronary Yes 5, (1.6%) Intervention No 12, (1.5%) Diabetes Mellitus Yes 7, (1.6%) No 11, (1.6%) Family History of premature CAD Yes (1.5%) 1 No 17, (1.6%)
25 Complication Univariate analysis (2003 ~ 06) No. of cases = 18,448 Complications: N=292 (1.6%) C. Procedure Summary No. of Complications cases N(%) p-value Indications Primary or Rescue AMI/Unplanned redo PCI (3.3%) <0.01 Elective/ACS other than AMI 17, (1.5%) Characteristic of the worst lesion Type A/B1 5, (0.8%) Type B2/C 12, (1.9%) <0.01
26 Complication Multivariate analysis (2003 ~ 06) No. of PCI cases = 18,437 (Complication = 291, 1.58%) OR 95 % C.I. p-value Heart failure Cerebrovascular disease Age Intercurrent Cardiogenic shock None/Other HF/Past Hx of HF Yes No >=70 Vs below 70 Vs Vs 2.14 (1.12, 4.10) (1.09, 2.29) (1.15, 1.83) Indications Charactreristic of worst lesion Goodness-of-fit Primary or Rescue AMI/Unplanned redo PCI Elective/ACS other than AMI Type B2/C Type A/B1 p-value of Hosmer & Lemeshow test 0.23 Area under ROC curve 0.63 Vs Vs 1.67 (1.08, 2.60) (1.57, 2.96) <.0001
27 Standardized Complication Ratio (SCR) (2003~2006) Excluding cases with missing heart failure, CVA, age, indications or Characteristic of worst lesion Heterogenous group of complications (from mild to severe) Hospital Expected no. of complications = sum of predicted probability of complications from multiple logistic regression Amodel for each hospital B C D E F G H I J
28 Development and Validation of a predictive model for Post-PCI mortality within 72 hours Excluding cases with unknown outcome within 72 hours post-pci PCI data for No. of PCI cases = 18,618 Deaths = 111 (0.6%) Training Dataset No. of PCI cases = 13,582 Deaths = 86 (0.6%) Validation Dataset 2006 No. of PCI cases = 5,036 Deaths = 25 (0.5%)
29 Receiver operating characteristic (ROC) curves of multiple logistic regression models in Sheet "Model" for training dataset (Years ) and validation dataset (Year 2006) 1 ROC curve Sensitivity Training dataset (area under curve=0.923) Validation dataset (area under curve=0.831) Specificity
30 Predictors of Mortality OR Intercurrent cardiogenic shock 12.1 Unstable Angina 6.4 Intercurrent VT/VF 4.3 Renal Failure 4.2 Hx of CVA 3.1 Left Main involvement 2.9 Primary/Rescue PCI for AMI 2.8
31 Predictors of non-death complications OR Type B2/C lesions 2.2 Intercurrent cardiogenic shock 2.1 Primary/Rescue PCI for AMI 1.7 Hx of CVA 1.6 Age
32 Limitations No data on 6-month 6 month redo-pci for Target Lesion Revascularization (TLR) Self-reported reported cases 2003 a full-time audit nurse to check data accuracy a part-time time audit nurse 2006 onwards data accuracy ensured by individual institutions
33 Way Forward Individual CCLs responsible for data accuracy A designated medical staff as point of contact Half-yearly outstanding report list to individual CCL for FU Collaborate with HI & IT Team GRR for PCI reports integrating audit capability (All the 10 CCLs are using the GRR PCI reporting system since January 2005) Data Quality cross-check check with data warehouse e.g. death registry, LIS, MOE Generic reports by CDARS Individual hospital vs. all hospital average With validated risk prediction model for PCI procedures in HA hospitals Uphold the standard of PCI procedures performed in HA hospitals Interventional Cardiologists more willing to take up high-risk cases Patients more well-informed of the risks of PCI
34 Acknowledgement Hong Kong Public Hospital Cardiologists Association HA Central Committee (Cardiac Services) HAHO Statistics and Research Section HAHO HI & IT Team HAHO Clinical Effectiveness Unit HAHO Central Audit Committee
35 Thank you!
HA Territory-wide PCI Audit 2003-05
HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working
More informationEvaluation of Predictive Models
Evaluation of Predictive Models Assessing calibration and discrimination Examples Decision Systems Group, Brigham and Women s Hospital Harvard Medical School Harvard-MIT Division of Health Sciences and
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationCopenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationImpact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care
Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Michelle A. Albert MD MPH Treacy S. Silbaugh B.S, John Z. Ayanian MD MPP, Ann Lovett RN
More informationDatabases in Clinical Research. Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support
Databases in Clinical Research Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support Overview Background: History and utility of clinical data repositories Strategies:
More informationThe Cardiac Society of Australia and New Zealand
The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationIs Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
More informationCardiac Rehab. Home. www.homecareforyou.com. Do you suffer from a cardiac condition that is limiting your independence in household mobility?
TM Nightingale Home Cardiac Rehab Do you suffer from a cardiac condition that is limiting your independence in household mobility? Such as, 1. A recent heart attack 2. A heart condition coronary artery
More informationPooled RESOLUTE Clinical Program
The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical
More informationHow can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris
How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore
More informationPCI vs. CABG for Left Main Disease
The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease
More informationAntonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationA Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationFFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationVascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial
Vascular Quality Initiative - Carotid Artery Stent Last Name First Name Middle Initial Date of Birth Medical Record Social Security General Information Patient Data Zip/Postal Code Gender Male Female Ethnicity
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationCOMMON METHODOLOGICAL ISSUES FOR CER IN BIG DATA
COMMON METHODOLOGICAL ISSUES FOR CER IN BIG DATA Harvard Medical School and Harvard School of Public Health sharon@hcp.med.harvard.edu December 2013 1 / 16 OUTLINE UNCERTAINTY AND SELECTIVE INFERENCE 1
More informationCalifornia Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
More informationPresenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
More informationMISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationChi Squared and Fisher's Exact Tests. Observed vs Expected Distributions
BMS 617 Statistical Techniques for the Biomedical Sciences Lecture 11: Chi-Squared and Fisher's Exact Tests Chi Squared and Fisher's Exact Tests This lecture presents two similarly structured tests, Chi-squared
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationPercutaneous coronary intervention (PCI) continues
Developing a Same-Day Discharge Program How to identify appropriate patients for safe and efficient discharge. BY CAROLYN A. DICKENS, MSN, APN, AND ADHIR SHROFF, MD, MPH Percutaneous coronary intervention
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationSpecialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents
Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents Introduction... 2 Specialty Excellence Award Determination... 3 America s 100 Best Hospitals
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationCARDIAC CARE. Giving you every advantage
CARDIAC CARE Giving you every advantage Getting to the heart of the matter The Cardiovascular Program at Northwest Hospital & Medical Center is dedicated to the management of cardiovascular disease. The
More informationHealth Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich
More informationThe Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
More informationCARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationUsing Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada
Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute
More informationProvider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469)
Provider Checklist-Outpatient Imaging Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Medical Review Note: Per InterQual, if any of the following are present,
More informationPhysician and other health professional services
O n l i n e A p p e n d i x e s 4 Physician and other health professional services 4-A O n l i n e A p p e n d i x Access to physician and other health professional services 4 a1 Access to physician care
More informationCardiac Rehabilitation: Strategies Approaching 2020
ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular
More informationTranslating Science to Health Care: the Use of Predictive Models in Decision Making
Translating Science to Health Care: the Use of Predictive Models in Decision Making John Griffith, Ph.D., Associate Dean for Research Bouvé College of Health Sciences Northeastern University Topics Clinical
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationMADIT-II CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY MADIT-II Boston Scientific Corporation
More informationTranscatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators
Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations Danny Dvir, MD On behalf of VIVID registry investigators Introduction Bioprosthetic valves are increasingly implanted in open-heart surgeries.
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationESC PCI Guidelines: / Sigmund Silber et al. 1
For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction
More informationStent for Life Initiative How can we improve system delay and patients delay in STEMI
Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More information2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
More informationPost-MI Cardiac Rehabilitation. Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust
Post-MI Cardiac Rehabilitation Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust 'the sum of activities required to influence favourably the underlying
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationOverview. Total Joint Replacement in the U.S. KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery?
KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery? Liz Paxton Director of Surgical Outcomes and Analysis Overview KP Total Joint Replacement Registry Background
More informationRISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
More informationPIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators
Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland Impact of distal embolization Distal embolization
More informationCARDIAC NURSING. Graduate Diploma in Nursing Science. Overview. Entry Requirements. Fees. Contact. Teaching Methods.
Graduate Diploma in Nursing Science CARDIAC NURSING Overview The Graduate Diploma in Nursing Science (Cardiac Nursing) is designed to develop advanced theoretical knowledge and specialist skills essential
More informationTips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD
Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes
More informationImpact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005. Tania Tang PHASE Symposium May 12, 2007
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005 Tania Tang PHASE Symposium May 12, 2007 Presentation Outline Background Research Questions Methods Results Discussion
More informationElevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality
Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality C. Tomas, MA Castel, E Roig, I. Vallejos, C. Plata, F. Pérez-Villa Cardiology Department,
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationAcute Coronary Syndrome. What Every Healthcare Professional Needs To Know
Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationClinical Programs. Medtronic Coronary Stent Systems. driver BMS
Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued
More informationManagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management
More informationEndoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter
Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter Endoskopische Venenentnahme (EVH) - Einführung 1979 Tevaearai und Kollegen haben
More information3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1
Post CABG Rehabilitation i Ahmed Elkerdany Professor of Cardiac Surgery Ain Shams University 1 Definition Cardiac rehabilitation services are comprehensive, long-term programs involving : medical evaluation.
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationNAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3
1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications
More informationCh. 138 CARDIAC CATHETERIZATION SERVICES 28 138.1 CHAPTER 138. CARDIAC CATHETERIZATION SERVICES GENERAL PROVISIONS
Ch. 138 CARDIAC CATHETERIZATION SERVICES 28 138.1 CHAPTER 138. CARDIAC CATHETERIZATION SERVICES Sec. 138.1 Principle. 138.2. Definitions. GENERAL PROVISIONS PROGRAM, SERVICE, PERSONNEL AND AGREEMENT REQUIREMENTS
More informationUnderstanding Mortality Statistics: The Importance of Cause-of-Death Certification and Coding
Understanding Mortality Statistics: The Importance of Cause-of-Death Certification and Coding Robert N. Anderson, PhD Arialdi M. Miniño, MPH Mortality Statistics Branch Division of Vital Statistics Centers
More informationPerioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing
Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis Michael A. Blazing Outline The coming crush A practical approach to clinical risk assessment Classic approach to
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationTable e-1: Description of the three participating centres Umeå, Sweden Dublin, Ireland Barcelona, Spain Population-based study with single
Table e-1: Description of the three participating centres Umeå, Sweden Dublin, Ireland Barcelona, Spain Population-based study with single Study setting stroke centre in a Population study small city,
More informationPreoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia
Preoperative Cardiac Stents Perioperative Management Mark A. Taylor, MD Department of Anesthesia Revasc prior to NCS If it offered long term benefit-- --made sense to do it 1-22 vessel CAD by angiogram,
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationAfter acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS
CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS By Deborah Chyun, RN, PhD, Viola Vaccarino, MD, PhD, Jaime Murillo, MD, Lawrence H. Young, MD, and Harlan M. Krumholz,
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
More informationValidation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery q
European Journal of Cardio-thoracic Surgery 22 (2002) 101 105 www.elsevier.com/locate/ejcts Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery
More informationMitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic
More informationA Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm
A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm Zi Ye, 1 MD, Erin Austin, 1,2 PhD, Daniel J Schaid, 2 PhD, Iftikhar J. Kullo, 1 MD Affiliations: 1 Division of Cardiovascular Diseases and
More informationDarlene Langhoff St. Thomas More High Ron Gerrits MSOE
Darlene Langhoff St. Thomas More High Ron Gerrits MSOE Investigating the Scene DNA analysis The Findings Crime scene is set up (optional power point ) Tip: Set up crime scene and have students take photos
More informationAVAILABILITY AND ACCESSIBILITY OF CARDIAC REHABILITATION SERVICES IN LOW- AND MIDDLE-INCOME COUNTRIES QUESTIONNAIRE
AVAILABILITY AND ACCESSIBILITY OF CARDIAC REHABILITATION SERVICES IN LOW- AND MIDDLE-INCOME COUNTRIES QUESTIONNAIRE To be completed by Staff Cardiologists at an adult cardiac institute/department. INSTRUCTIONS:
More informationPREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care
PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care Ronald L Walsh, D.O., MACOI, FACC ACOI Clinical Challenges in Inpatient Care March
More informationPress conference: Rheumatic Heart Disease a forgotten but devastating disease
www.worldcardiocongress.org Chairpersons: Bongani M. Mayosi Jonathan Carapetis Press conference: Rheumatic Heart Disease a forgotten but devastating disease www.worldcardiocongress.org www.worldcardiocongress.org
More informationCARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN
HOSPITALIZATION CASE #: 2 8 8 0 H FY288BH4CN Has the participant indicated any of the following reasons for being admitted overnight for this case? 1. Suspected or confirmed problems with the heart, circulation,
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationRepeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation
Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark
More information